Hipa.ai Research · Source: PubMed & ClinicalTrials.gov / AACT · Last updated:
The clinical evidence base for Tasquinimod comprises 7 peer-reviewed publications across 6 journals, 1 pivotal-trial primary-outcome rows reported to ClinicalTrials.gov, spanning indications including Prostatic Neoplasms, Multiple Myeloma, and Neoplasm Metastasis. Most recent publication: Tasquinimod suppresses tumor cell growth and bone resorption by targeting immunosuppressive myeloid cells and inhibiting c-MYC expression in multiple myeloma., J Immunother Cancer, 2023.
Curated set of pivotal-trial result papers and recent publications in high-tier journals.
Per-arm reported values from Phase 2/3 and Phase 3 trials with results posted to ClinicalTrials.gov.
| Trial | Indication | Primary endpoint | Arm | Value |
|---|---|---|---|---|
| NCT02057666 TasQ003 | Prostatic Neoplasms | Time to Radiological Progression-Free Survival (PFS) From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 3 years | Placebo | 7.53 months |
| Tasquinimod | 11.00 months |
2011–2023: 7 publications.
Tasquinimod has been investigated in clinical studies for prostatic neoplasms. One pivotal trial, NCT02057666 (TasQ003), evaluated the time to radiological progression-free survival. This endpoint measured the time from randomization until the first documented progression or death, assessed up to 3 years.
In the NCT02057666 trial, participants receiving Tasquinimod had a median time to radiological progression-free survival of 11.00 months. For participants in the placebo arm of NCT02057666, the median time to radiological progression-free survival was 7.53 months.
All values are sourced from primary registry reporting, and individual papers should be consulted for clinical decisions.
ctgov.study_references (PubMed PMIDs auto-attached by ClinicalTrials.gov to each trial), reference types RESULT, DERIVED, and BACKGROUND.ctgov.outcome_measurements joined to ctgov.design_outcomes where outcome_type = 'PRIMARY', restricted to phase PHASE3 and PHASE2/PHASE3.efetch.fcgi